Carvolix Emerges with Strategic Acquisitions and Funding

Carvolix, previously known as Affluent Medical, has announced its rebranding alongside the completion of strategic acquisitions and financings. The company has acquired Caranx Medical and Artedrone, forming a new entity focused on innovative AI-driven medtech solutions. A first financing tranche of €10M was secured from Truffle Capital and Edwards Lifesciences, priced at €2.34 per share, an 18.8% premium.

The integration aims to revolutionize interventional cardiology and stroke treatment, addressing large markets worth €23 billion. Key focus areas include cardiac valve replacements and brain stroke interventions, aiming to democratize complex procedures worldwide.

Carvolix is set to launch its first product, TAVIPILOT software, in early 2026 in the US with plans for further international expansion. The company's strategic moves include enhancing cardiac catheterization labs, aiming for broader patient impact and robust innovation cycles.